By studying the effects of the nasal anti-CD3 in a ... Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped ...

SAVANNAH, Ga. (WTOC) - March is Multiple Sclerosis awareness month. It’s an autoimmune disease that impacts nearly a million people around the world. This month, our Jasmine Butler is bringing us ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for multiple sclerosis (MS). While current treatments prevent further damage ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

In recently published research in the journal Neurology, the team tracked records for 4,593 people living with multiple sclerosis from 2019 to 2020, 673 in rural areas and 3,920 in urban centers.

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on Saturday won a prestigious Breakthrough Prize, the award nicknamed the ...

Hauser's work on multiple sclerosis (MS) started more than 45 years ago, when he met a young patient named Andrea, "an extraordinarily talented young woman who was already an attorney" and working ...

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the ...

“This is an outcome that has not been seen before in prior therapies that have been used to improve function in multiple sclerosis,” Greenberg said. Data further showed that 96% of ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.